The primary CR was achieved in 832/866 (96.1%) patients and 1163/1197 (97.2%) tumor lesions, the remaining 34/866 (3.9%) patients and 34/1197 (2.8%) residual tumor lesions were identified as TF and were excluded form further analysis. The gene discussed is TF; the disease is neoplasm.